Cellectis SA (NAS:CLLS)
$ 1.56 0 (0%) Market Cap: 154.13 Mil Enterprise Value: -15.24 Mil PE Ratio: 0 PB Ratio: 1.27 GF Score: 70/100

Cellectis SA at Jefferies Cell & Genetic Medicine Summit Transcript

Sep 26, 2023 / 06:00PM GMT
Release Date Price: $1.62 (+1.25%)
Dev Prasad Jefferies LLC;Analyst

[Good afternoon] everyone. My name is Dev Prasad. I'm an associate on our Senior Analyst Kelly Shi's team here at Jefferies, and thank you for attending our Cell and Gene Medicine Summit in New York. We are very pleased to have Dr. Mark Frattini, CMO from Cellectis, joining us today to share insight on Cellectis. Welcome.

Mark Frattini Cellectis S.A.;Chief Medical Officer

Hi there. Nice to be here. Thank you.

Questions & Answers

Dev Prasad Jefferies LLC;Analyst

Maybe we can start off with one of the more important debate going on in the industry, which is autologous versus allogeneic CAR-T approaches. And if you can provide the opportunity for alloCART and continue the discussion. And what's the differentiation of TALEN gene editing platform versus the others that are working to bring allogeneic CAR-T to market?

Mark Frattini Cellectis S.A.;Chief Medical Officer

Sure. Thanks for the question. So in

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot